Literature DB >> 2228845

Multiresistant Salmonella typhimurium systemic infection in Rwanda. Clinical features and treatment with cefotaxime.

P Lepage1, J Bogaerts, C Van Goethem, D G Hitimana, F Nsengumuremyi.   

Abstract

Children with multiresistant Salmonella typhimurium (MRST) systemic infections, in total 246, were diagnosed during the study period. Of these, 220 had MRST without metastatic focal infections and 26 had metastatic focal infections (including 12 patients with meningitis). The median age of the children was 10 months. Diarrhoeal disease, measles and severe malnutrition were the most frequent causes of admission. Fever was found in 99% and diarrhoea in 72% of the patients, with respiratory symptoms in 72%. In 199 (81%) of the patients, the MRST infection was considered to be hospital-acquired. Of the 246 children, 159 were treated with cefotaxime. In this group, 16 of 152 patients died (10.5%). However, of the 87 children who did not receive cefotaxime, 64 died (74%). Relapses occurred in 4% of the patients with bacteraemia treated with cefotaxime. Our study confirms the high efficiency of cefotaxime in treating severe systemic infections with MRST.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2228845     DOI: 10.1093/jac/26.suppl_a.53

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Five-Year Antimicrobial Susceptibility Trends Among Bacterial Isolates from a Tertiary Health-Care Facility in Kigali, Rwanda.

Authors:  Makeda Carroll; Ashok Rangaiahagari; Emmanuel Musabeyezu; Donald Singer; Onyema Ogbuagu
Journal:  Am J Trop Med Hyg       Date:  2016-10-31       Impact factor: 2.345

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 3.  Invasive non-Typhi Salmonella disease in Africa.

Authors:  Susan C Morpeth; Habib O Ramadhani; John A Crump
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

Review 4.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

5.  In vitro activity of azithromycin against bacterial enteric pathogens.

Authors:  M E Gordillo; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

6.  Intracellular activity of azithromycin against bacterial enteric pathogens.

Authors:  R M Rakita; K Jacques-Palaz; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

7.  A review of 40 years of enteric antimicrobial resistance research in Eastern Africa: what can be done better?

Authors:  Sylvia Omulo; Samuel M Thumbi; M Kariuki Njenga; Douglas R Call
Journal:  Antimicrob Resist Infect Control       Date:  2015-01-28       Impact factor: 4.887

Review 8.  A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014).

Authors:  Ifeanyi Valentine Uche; Calman A MacLennan; Allan Saul
Journal:  PLoS Negl Trop Dis       Date:  2017-01-05

9.  Invasive non-typhoidal Salmonella infections in sub-Saharan Africa: a systematic review on antimicrobial resistance and treatment.

Authors:  Bieke Tack; Jolien Vanaenrode; Jan Y Verbakel; Jaan Toelen; Jan Jacobs
Journal:  BMC Med       Date:  2020-07-17       Impact factor: 8.775

10.  Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis.

Authors:  Christian S Marchello; Megan Birkhold; John A Crump
Journal:  Lancet Infect Dis       Date:  2022-02-01       Impact factor: 71.421

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.